Thor Medical Enters into an Agreement with Node Pharma for Supply of Radium-224 and Lead-212

26 Mar 2026 07:00 CET

26.3.2026 07:00:00 CET | Thor Medical ASA | Non-regulatory press releases

Oslo, March 26, 2026: Thor Medical, a leading emerging supplier of
alpha-emitters for next-generation precision cancer treatment, has entered into
a multiyear frame agreement with Node Pharma, a Norwegian radiopharmaceutical
company, for the supply of radium-224 (Ra-224) and lead-212 (Pb-212) for
preclinical use.

The agreement follows successful product sample deliveries from Thor Medical's
pilot facility at Herøya Industrial Park to Node Pharma and supports further
expansion of Node Pharma's development pipeline for alpha-emitting therapies.
Radium-224 and lead-212, together with thorium-228, are part of Thor Medical's
portfolio of products.

"The agreement is a further validation of our capabilities to deliver
high-quality products from our facility at Herøya, but most importantly it
confirms a market trend we have observed over time, namely the growing demand
for isotopes such as radium-224 and lead-212. With Node Pharma as a partner, we
are supporting an exciting development program while gaining valuable insight
into future product needs," said Jasper C. Kurth, CEO of Thor Medical.

"Reliable isotope supply is a critical enabler for our pipeline strategy. This
agreement with Thor Medical broadens our access to key alpha-emitting isotopes
and supports the continued expansion of our alpha pipeline," said Erik Mjåland,
Chief Business Officer and Co-founder of Node Pharma.

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium. Its proprietary production process requires no
irradiation or use of nuclear reactors, and provides reliable, environmentally
friendly, cost-efficient supply of alpha emitters for the radiopharmaceutical
industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange under the ticker symbol 'TRMED'. To learn more, visit
www.thormedical.com - http://www.thormedical.com - http://www.thormedical.com.

ABOUT NODE PHARMA AS

Node Pharma is a radiopharmaceutical company developing first-in-class targeted
alpha therapies for cancer patients with limited treatment options. Its lead
asset, targeting liver cancer, is designed to be plug-and-play with existing
clinical infrastructure and workflow, upgrading current approaches from beta to
alpha radiation. Its isotope-agnostic platform supports expansion across
multiple isotopes and indications. The company is chaired by Dr. Thomas Ramdahl,
the first CEO of Algeta ASA, the company behind Xofigo® (Ra-223), which Bayer
acquired for approximately US$2.9 bn in 2014.

CONTACTS

Thor Medical ASA
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, Thor
Medical ASA, +47 988 05 724, mathias.reierth@thormedical.com

Node Pharma AS
Erik Mjåland, CBO & Co-founder, Node Pharma AS, +47 900 17 688,
erik@nodepharma.no

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18845895/6916/Download%20announce
ment%20as%20PDF.pdf

More information:
Access the news on Oslo Bors NewsWeb site

669340_Download announcement as PDF.pdf